Patents by Inventor Ulrich Luecking

Ulrich Luecking has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as a medicine
    Patent number: 8802686
    Abstract: The invention relates to sulphone-substituted anilinopyrimidine derivatives of the formula (I), to its preparation processes, and to its use as medicament for treating various diseases.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: August 12, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulrich Lücking, Gerhard Siemeister, Philip Lienau, Rolf Jautelat, Julia Schulze
  • Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine
    Patent number: 8735412
    Abstract: The invention relates to sulfoximine-substituted anilino-pyrimidine derivatives of formula (I). methods of production thereof, and use thereof as medication for the treatment of various diseases.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: May 27, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulrich Lücking, Rolf Jautelat, Gerhard Siemeister, Julia Schulze, Philip Lienau
  • SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES
    Publication number: 20140045852
    Abstract: The present invention relates to substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: April 18, 2012
    Publication date: February 13, 2014
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bomer, Gerd Rühter, Carsten Schultz-Fademrecht, Dirk Kosemund, Philip Lienau
  • Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
    Patent number: 8642611
    Abstract: The invention relates to alkynylpyrimidines according to the general formula (I): in which A, R1, R2, R3, R4, R5, and R6 are as defined in the claims, and salts, N-oxides, metabolites, solvates, tautomers and prodrugs thereof, to pharmaceutical compositions comprising said alkynylpyrimidines, to methods of preparing said alkynylpyrimidines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 and VEGFR2 signalling.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: February 4, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ingo Hartung, Ulrich Bothe, Georg Kettschau, Ulrich Luecking, Anne Mengel, Martin Krueger, Karl Thierauch, Philip Lienau, Ulf Boemer
  • Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
    Patent number: 8524724
    Abstract: The invention relates to alkynylpyrimidines according to the general formula (I): in which A, R1, R2, R3, R4, R5, and R6 are as defined in the claims, and salts, N-oxides, metabolites, solvates, tautomers and prodrugs thereof, to pharmaceutical compositions comprising said alkynylpyrimidines, to methods of preparing said alkynylpyrimidines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 and VEGFR2 signalling.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: September 3, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ingo Hartung, Ulrich Bothe, Georg Kettschau, Ulrich Luecking, Anne Mengel, Martin Krueger, Karl Thierauch, Philip Lienau, Ulf Boemer
  • USE OF NOVEL PAN-CDK INHIBITORS FOR TREATING TUMORS
    Publication number: 20130210846
    Abstract: The invention relates to the use of selected sulfoximine-substituted anilinopyrimidine derivatives of the formula (I) for treating tumors.
    Type: Application
    Filed: March 28, 2011
    Publication date: August 15, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ulrich Lücking, Gerhard Siemeister, Antje Margret Wengner
  • Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
    Patent number: 8507510
    Abstract: This invention relates to pyrimidine derivatives of general formula I in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: August 13, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulrich Lücking, Martin Krüger, Rolf Jautelat, Gerhard Siemeister
  • Substituted (Heteroarylmethyl)thiohydantoins
    Publication number: 20120251551
    Abstract: The invention relates to substituted (heteroarylmethyl) thiohydantoin compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, and their use for the preparation of medicaments for the treatment and/or prophylaxis of disorders, in particular of prostate cancer.
    Type: Application
    Filed: August 28, 2010
    Publication date: October 4, 2012
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Arwed Cleve, Bernard Haendler, Hortensia Faus Gimenez, Silke Köhr, Horst Irlbacher
  • (Heteroarylmethyl) Thiohydantoins as anticancer drugs
    Publication number: 20120238533
    Abstract: The invention refers to the use of androgen receptor antagonists for the treatment and/or prevention of fibroids, also known as uterine leiomyoma, leiomyomata. Particularly, the invention refers to the use of an androgen receptor antagonist being any one of the compounds according to the following list: cyproterone acetate, oxendolone, chlormadinone acetate, spironolactone, osaterone acetate, dienogest, flutamide, hydroxyflutamide, nilutamide, bicalutamide, RU 58841, LGD-2226, MDV3100, BMS-641988, BMS-779333, or 4-(3-{[6-(2-hydroxy-2-methylpropoxy)pyridin-3-yl]methyl}-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (thioxoimidazolidine derivative) for the treatment of fibroids.
    Type: Application
    Filed: September 3, 2010
    Publication date: September 20, 2012
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Arwed Cleve, Ulrich Lücking, Stefan Bäurle, Martin Fritsch, Jens Schröder, Bernd-Wolfgang Igl
  • SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE
    Publication number: 20110294838
    Abstract: The invention relates to sulfoximine-substituted anilino-pyrimidine derivatives of formula (I). methods of production thereof, and use thereof as medication for the treatment of various diseases.
    Type: Application
    Filed: October 9, 2009
    Publication date: December 1, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Rolf Jautelat, Gerhard Siemeister, Julia Schulze, Philip Lienau
  • SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE
    Publication number: 20110251222
    Abstract: The invention relates to sulphone-substituted anilinopyrimidine derivatives of the formula (I), to its preparation processes, and to its use as medicament for treating various diseases.
    Type: Application
    Filed: October 8, 2009
    Publication date: October 13, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Gerhard Siemeister, Philip Lienau, Rolf Jautelat, Julia Schulze
  • Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors
    Patent number: 8003787
    Abstract: The present invention relates to a quinoline or quinazoline derivative having the general formula (A): in which R3, R4, W, Y and Q are indicated in the description and the claims, the use of the compounds of the general formula (A) for the treatment of various disorders, and the preparation of compounds of the general formula (A).
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: August 23, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Knut Eis, Olaf Prien, Ulrich Lücking, Judith Günther, Dieter Zopf, Dirk Brohm, Verena Vöhringer, Elisabeth Woltering, Hartmut Beck, Mario Lobell, Volkhart Min-Jian Li, Susanne Greschat
  • Substituted sulphoximines as TIE2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
    Patent number: 8003655
    Abstract: The invention relates to substituted sulphoximines according to the general formula (I): in which A, E, G, X, R1, R2, R3, R4, R5, R6, R7, R8, m, p, q, are given in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted sulphoximines, to methods of preparing said substituted sulphoximines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: August 23, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Ingo Hartung, Georg Kettschau, Hans Briem, Karl-Heinz Thierauch, Ulrich Luecking, Ulf Boemer, Martin Krueger
  • Sulphimides as protein kinase inhibitors
    Patent number: 7943629
    Abstract: The invention relates to sulphimides as protein kinase inhibitors of the general formula I
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: May 17, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Ulrich Luecking, Duy Nguyen, Arne von Bonin, Oliver von Ahsen, Gerhard Siemeister, Rolf Jautelat, Wolf-Dietrich Doecke
  • Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
    Patent number: 7825128
    Abstract: The invention relates to sulfoximine-substituted pyrimidines of the general formula I processes for the preparation thereof and their use as drugs.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: November 2, 2010
    Assignee: Bayer Schering Pharma AG
    Inventors: Ulrich Lücking, Duy Nguyen, Arne Von Bonin, Oliver Von Ahsen, Martin Krüger, Hans Briem, Georg Kettschau, Olaf Prien, Anne Mengel, Krolikiewicz Konrad, Ulf Boemer, Ulrich Bothe, Ingo Hartung
  • Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
    Patent number: 7750000
    Abstract: The invention relates to novel inhibitors of kinases, and pharmaceutical compositions comprising them. The inhibitors are substituted imidazo[1,2b]pyridazines.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: July 6, 2010
    Assignee: Bayer Schering Pharma AG
    Inventors: Olaf Prien, Stuart James Ince, Knut Eis, Christoph Huwe, Ulrich Lücking, Rolf Jautelat, Ulrich Zügel, Judith Günther, Benjamin Bader, Manfred Husemann, Karina Schuck
  • SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS
    Publication number: 20100076000
    Abstract: This invention relates to pyrimidine derivatives of general formula I in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
    Type: Application
    Filed: October 12, 2004
    Publication date: March 25, 2010
    Inventors: Ulrich Lücking, Martin Krüger, Rolf Jautelat, Gerhard Siemeister
  • CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents
    Patent number: 7598260
    Abstract: This invention relates to pyrimidine derivatives of general formula I in which R1, R2, X, A and B have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinases, their production as well as their use as medications for treating various diseases.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: October 6, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Thomas Brumby, Rolf Jautelat, Olaf Prien, Martina Schäfer, Gerhard Siemeister, Ulrich Lücking, Christoph Huwe
  • ALKYNYLPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME
    Publication number: 20090099219
    Abstract: The invention relates to alkynylpyrimidines according to the general formula (I): in which A, R1, R2, R3, R4, R5, and R6 are as defined in the claims, and salts, N-oxides, metabolites, solvates, tautomers and prodrugs thereof, to pharmaceutical compositions comprising said alkynylpyrimidines, to methods of preparing said alkynylpyrimidines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 and VEGFR2 signalling.
    Type: Application
    Filed: June 19, 2008
    Publication date: April 16, 2009
    Inventors: Ingo Hartung, Ulrich Bothe, Georg Kettschau, Ulrich Luecking, Anne Mengel, Martin Krueger, Karl Heinz Thierauch, Philip Lienau, Ulf Boemer
  • N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents
    Patent number: 7456191
    Abstract: This invention relates to pyrimidine derivatives of general formula (I) in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: November 25, 2008
    Assignee: Schering AG
    Inventors: Ulrich Luecking, Gerhard Siemeister, Rolf Jautelat